Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer

Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival ( relative risk 1.9, 95% CI: 1.2 - 3.0), particularly among women who received adjuvant chemotherapy ( 10-year survival 27 vs 69%, P = 0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions.